JT003, a dual AdipoR agonist, was found to be effective in the treatment of NASH and liver fibrosis by suppressing fatty acid synthesis genes and augmenting fatty acid oxidation genes via activating the AMPK/PPARα signaling pathway. Here, PRKAB1 is linked to metabolic dysfunction-associated steatohepatitis.